Cann said:
“We had anticipated a PDUFA date for this sNDA filing in H2 2018; as a result of the January 2019 PDUFA date we are slightly adjusting sales and EPS for 2018. Based on the timing of the PDUFA date, we are slightly delaying our estimated launch for Cabometyx in HCC. As a result we are decreasing our estimated 2018 revenue estimate by 3.5%, to $649.0 million from $672.8 million. We are reducing our estimated EPS in 2018 by 9.6%, to $0.67 from our prior estimate of $0.74. Our outlook for 2019 – 2022 revenue is unchanged.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 21.1% and a 63.2% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Exelixis has an analyst consensus of Strong Buy, with a price target consensus of $32.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.50 and a one-year low of $18.03. Currently, Exelixis has an average volume of 3.66M.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. Earlier this month, George Scangos, a Director at EXEL bought 15,000 shares for a total of $174,900.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.